A prospective economic analysis of early outcome data from the Alliance A041202/ CCTG CLC.2 randomized phase III trial of bendamustine-rituximab compared with ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia
- Citation:
- Clin Lymphoma Myeloma Leuk vol 21 (11) 766-774
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 3396
- Children:
- None
- Pharmas:
- Pharmacyclics, Inc.
- Grants:
- U10CA180821, U10CA180882, UG1CA233331; U10CA180863, #704970 (CCTG)
- Corr. Author:
- Authors:
- Matthew C. Cheung Nicole Mittmann Carolyn Owen Nizar Abdel-Samad Graeme A. M. Fraser Selay Lam Michael Crump Catherine Sperlich Richard van der Jagt Anca Prica Stephen Couban Jennifer A. Woyach Amy S. Ruppert Allison M. Booth Sumithra J. Mandrekar Gail McDonald Lois E. Shepherd Hope Yen Bingshu E. Chen Annette E. Hay
- Networks:
- LAPS-MN026, LAPS-OH007
- Study
- Alliance-A151905
- Multiple Studies, or Legacy Studies in Alliance Study:
- Alliance-A041202
- Phases:
- N/A, 3
- Keywords:
- Economic analysis, chronic lymphocytic leukemia, ibrutinib, bendamustine-rituximab, phase III trial